Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Current status of acute hepatitis C].
Martínez-Rebollar M, Larrousse M, Calvo M, Muñoz A, González A, Loncà M, Martínez E, Blanco JL, Mallolas J, Laguno M. Martínez-Rebollar M, et al. Among authors: calvo m. Enferm Infecc Microbiol Clin. 2011 Mar;29(3):210-5. doi: 10.1016/j.eimc.2010.12.005. Epub 2011 Feb 18. Enferm Infecc Microbiol Clin. 2011. PMID: 21334112 Review. Spanish.
Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, Bonet L, Vidal F, Milinkovic A, Bassa A, Villalonga C, Pérez I, Tural C, Martínez-Rebollar M, Calvo M, Blanco JL, Martínez E, Sánchez-Tapias JM, Gatell JM, Mallolas J. Laguno M, et al. Among authors: calvo m. Hepatology. 2009 Jan;49(1):22-31. doi: 10.1002/hep.22598. Hepatology. 2009. PMID: 19085908 Clinical Trial.
Update on metabolic issues in HIV patients.
Calvo M, Martinez E. Calvo M, et al. Curr Opin HIV AIDS. 2014 Jul;9(4):332-9. doi: 10.1097/COH.0000000000000075. Curr Opin HIV AIDS. 2014. PMID: 24824886 Review.
Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir.
Blanco JL, Gonzalez-Cordón A, Llibre JM, Calvo M, Gutierrez F, Podzamczer D, Laguno M, Fumero E, Murillas J, Mallolas J, Martinez-Rebollar M, Lonca M, Perez I, Gatell JM, Martinez E. Blanco JL, et al. Among authors: calvo m. Antivir Ther. 2015;20(5):487-92. doi: 10.3851/IMP2812. Epub 2014 Jun 25. Antivir Ther. 2015. PMID: 24964358 Clinical Trial.
Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
Martinez-Rebollar M, Lonca M, Perez I, Soy D, Brunet M, Martin R, Coll O, Hernandez S, Laguno M, Milinkovic A, Larrousse M, Calvo M, Blanco JL, Martínez E, Gatell JM, Mallolas J. Martinez-Rebollar M, et al. Among authors: calvo m. Ther Drug Monit. 2011 Dec;33(6):772-7. doi: 10.1097/FTD.0b013e318236376d. Ther Drug Monit. 2011. PMID: 22105596
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
Martínez-Rebollar M, Muñoz A, Pérez I, Hidalgo S, Brunet M, Laguno M, González A, Calvo M, Loncà M, Blanco JL, Martínez E, Gatell JM, Mallolas J. Martínez-Rebollar M, et al. Among authors: calvo m. Ther Drug Monit. 2013 Aug;35(4):552-6. doi: 10.1097/FTD.0b013e31828d50ef. Ther Drug Monit. 2013. PMID: 23851911
1,392 results